GSK fined Â£22m over paroxetine 'pay for delay' deal
The Competition Appeal Tribunal has upheld a previous finding that GlaxoSmithKline paid generic drugs companies £50m to delay bringing paroxetine to the market.
The Competition and Markets Authority issued a decision in 2016 that payments made by GSK to generics manufacturers in settlement of patient litigation were aimed at delaying its competitors from entering the market with the antidepressant and were unlawful.
This was challenged by GSK and other companies including Generics (UK) Limited (GUK) and Alpharma Limited (Alpharma) via an appeal, but today this was quashed as the tribunal’s judgement unanimously dismissed all their grounds of appeal.
However, after “taking various factors into account” the tribunal has imposed reduced fines on the companies involved, with GSK now forced to pay £22.2m rather than the £37m fine levied by the CMA.
The tribunal had already dismissed a number of the companies’ grounds of appeal in 2018 and referred the remaining grounds to the Court of Justice of the European Union, which in 2020 confirmed this type of ‘pay for delay’ agreement “has the object of restricting competition and may constitute an abuse of a dominant position”. The tribunal’s judgement is published today.
The Department of Health and Social Care “will now be able to seek follow-on damages in the courts,” said the CMA.
CME executive director of enforcement Michael Grenfell said: “We welcome the Tribunal’s findings that GSK and a number of generic suppliers broke competition law. These agreements can cost the NHS and taxpayers millions of pounds.
“Today’s judgment sends out a strong message that agreements between pharmaceutical companies aimed at delaying generic entry are unlawful and won’t be tolerated.
“We note that the Tribunal recognises that significant fines were warranted, but are disappointed that it has reduced the fines imposed by the CMA for these serious breaches of competition law. We will now take stock of today’s judgment and carefully consider next steps.”
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Government 'risking pharmacy teams by easing restrictions'
The government’s easing of restrictions could risk pharmacy teams contracting covid-19, the PDA warns.
1 Min Article
'High prophylactic use of antibiotics' in care homes, Boots finds
A study commissioned by Boots UK has found “high prophylactic use of antibiotics” in UK care facilities prompting calls to offer staff better training.
1 Min Article
Covid jabs prevent hospitalisation from Delta strain
Both AZ and Pfizer vaccines over 90 per cent effective against hospitalisation from Delta variant, new PHE analysis reveals for the first time.
1 Min Article
Designated pharmacies to start Covid jabs on January 11
Community pharmacy-led Covid-19 vaccination sites will begin operations on Monday January 11, NHS England & Improvement has confirmed.
1 Min Article
Helping customers treat & care for their scalp
Understanding the causes and symptoms of some common scalp conditions will help you to make a real difference to your customers’ lives. Complete this module to discover self-care and product advice to help ease symptoms and maintain scalp health.
37 Min Module
Managing heartburn and indigestion in the pharmacy
Learn how to identify and help customers manage heartburn and indigestion, from recommending the right products to ease symptoms, to self-care advice and identifying red flags for referral
22 Min Module
Abdominal discomfort: Multi-symptom relief with Buscomint
Discover the key benefits of a product that offers multi-symptom relief from abdominal pain, cramps and bloating, plus lifestyle advice to help manage symptoms.
10 Min Module
OTC Omeprazole tablets 20mg: an opportunity for pharmacy
This module highlights a new opportunity to treat heartburn and reflux in the pharmacy with Omeprazole 20mg, which is newly available for customers to purchase OTC.
8 Min Module